Role of human cytochrome P4502A6 in C-oxidation of nicotine.
paper
Cited
Public
Unavailable
- Authors
- Nakajima, M; Yamamoto, T; Nunoya, K; Yokoi, T; Nagashima, K; Inoue, K; Funae, Y; Shimada, N; Kamataki, T; Kuroiwa, Y
- Year
- 1996
- Journal
- Drug metabolism and disposition: the biological fate of chemicals
- PMID
- 8937855
Nicotine is primarily metabolized to cotinine in humans. In this study, human cytochrome P450 (CYP) isoform involved in cotinine formation was identified. The formation of cotinine in 16 human liver microsomes was determined with a 50 microM nicotine concentration and with a cytosol preparation as a source of aldehyde oxidase. Cotinine formation in human liver microsomes significantly correlated with immunochemically determined CYP2A6 levels (r = 0.663, p < 0.05), coumarin 7-hydroxylase activities (r = 0.831, p < 0.01), and cotinine 3'-hydroxylase activities (r = 0.735, p < 0.01) that are responsible for CYP2A6. In inhibition studies, cotinine formation in human liver microsomes was inhibited by coumarin and rabbit anti-rat CYP2A1 antibody specifically. When the capability of microsomes of B-lymphoblastoid cells expressing human CYPs to perform biotransformation of nicotine to cotinine was determined, cDNA-expressed CYP2A6 exhibited the highest cotinine formation. The KMapp values from microsome expressing CYP2A6 cDNA were similar to the value obtained from human liver microsomes. The large interindividual variabilities in cotinine formation and immunochemically determined CYP2A6 levels were observed in human liver microsomes, suggesting genetic polymorphism of CYP2A6. Nicotine is a new in vivo probe for phenotyping of CYP2A6 in humans.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Alteration of Antioxidant and Xenobiotic Metabolizing Enzyme Activities in Rainbow Trout (Oncorhynchus mykiss) Treated With Caffeine and Cotinine During the Spawning Season. | Bozcaarmutlu-BΓΌken A et al. | β | 2026 | β |
| Nicotine as a female reproductive toxicant-A review. | Bhardwaj JK et al. | β | 2025 | β |
| A web-based scoping review assessing the influence of smoking and smoking cessation on antidiabetic drug meabolism: implications for medication efficacy. | Bellanca CM et al. | β | 2024 | β |
| PharmVar GeneFocus: CYP2A6. | Langlois AWR et al. | β | 2024 | β |
| Cigarette Smoking and Intracranial Aneurysms: A Pilot Analysis of SNPs in the CYP2A6 Gene in the Italian Population. | Ferrari E et al. | β | 2023 | β |
| CYP2C19 Plays a Major Role in the Hepatic <i>N</i>-Oxidation of Cotinine. | Perez-Paramo YX et al. | β | 2023 | β |
| Functional Characterization of Allelic Variations of Human Cytochrome P450 2C8 (V181I, I244V, I331T, and L361F). | Lee YB et al. | β | 2023 | β |
| Influence of CYP2A6 Genetic Variation, Nicotine Dependence Severity, and Treatment on Smoking Cessation Success. | Chenoweth MJ et al. | β | 2023 | β |
| Inhibition of Nicotine Metabolism by Cannabidiol (CBD) and 7-Hydroxycannabidiol (7-OH-CBD). | Nasrin S et al. | β | 2023 | β |
| Accuracy and applications of sequencing and genotyping approaches for CYP2A6 and homologous genes. | Langlois AWR et al. | β | 2022 | β |
| Functional characterization of novel rare CYP2A6 variants and potential implications for clinical outcomes. | El-Boraie A et al. | β | 2022 | β |
| Relating individual differences in the reinforcing value of smoking and dependence severity to nicotine exposure levels in vulnerable populations. | Browning KO et al. | β | 2022 | β |
| Serum Concentrations of Cotinine and Trans-3'-Hydroxycotinine in US Adults: Results From Wave 1 (2013-2014) of the Population Assessment of Tobacco and Health Study. | Sosnoff CS et al. | β | 2022 | β |
| Analyses of nicotine metabolism biomarker genetics stratified by sex in African and European Americans. | Chenoweth MJ et al. | β | 2021 | β |
| Biochemistry of nicotine metabolism and its relevance to lung cancer. | Murphy SE | β | 2021 | β |
| Cotinine: Pharmacologically Active Metabolite of Nicotine and Neural Mechanisms for Its Actions. | Tan X et al. | β | 2021 | β |
| Genome-wide association meta-analysis of nicotine metabolism and cigarette consumption measures in smokers of European descent. | Buchwald J et al. | β | 2021 | β |
| Nicotine metabolite ratio: Comparison of the three urinary versions to the plasma version and nicotine clearance in three clinical studies. | Giratallah HK et al. | β | 2021 | β |
| Pharmacogenetics factors influencing smoking cessation success; the importance of nicotine metabolism. | Perez-Paramo YX et al. | β | 2021 | β |
| PPARΞ± agonist WY-14,643 enhances ethanol metabolism in mice: Role of catalase. | Chen X et al. | β | 2021 | β |
| Transferability of Ancestry-Specific and Cross-Ancestry CYP2A6 Activity Genetic Risk Scores in African and European Populations. | El-Boraie A et al. | β | 2021 | β |
| Cytochrome P450 2A6 whole-gene deletion (CYP2A6*4) polymorphism reduces risk of lung cancer: A meta-analysis. | Johani FH et al. | β | 2020 | β |
| Evaluation of a weighted genetic risk score for the prediction of biomarkers of CYP2A6 activity. | El-Boraie A et al. | β | 2020 | β |
| Flavin-containing monooxygenase 3 (FMO3): genetic variants and their consequences for drug metabolism and disease. | Phillips IR et al. | β | 2020 | β |
| Impact of E-Cigarette Liquid Flavoring Agents on Activity of Microsomal Recombinant CYP2A6, the Primary Nicotine-Metabolizing Enzyme. | Winters BR et al. | β | 2020 | β |
| Mechanisms of Herb-Drug Interactions Involving Cinnamon and CYP2A6: Focus on Time-Dependent Inhibition by Cinnamaldehyde and 2-Methoxycinnamaldehyde. | Espiritu MJ et al. | β | 2020 | β |
| Prenatal smoke exposure induces persistent <i>Cyp2a5</i> methylation and increases nicotine metabolism in the liver of neonatal and adult male offspring. | Lkhagvadorj K et al. | β | 2020 | β |
| Relating individual differences in nicotine dependence severity to underpinning motivational and pharmacological processes among smokers from vulnerable populations. | Higgins ST et al. | β | 2020 | β |
| The Impact of Sex on Changes in Plasma Corticosterone and Cotinine Levels Induced by Nicotine in C57BL/6J Mice. | Nguyen K et al. | β | 2020 | β |
| Continuous exposure of nicotine and cotinine retards human primary pterygium cell proliferation and migration. | Yang Q et al. | β | 2019 | β |
| Does the nicotine metabolite ratio moderate smoking cessation treatment outcomes in real-world settings? A prospective study. | Shahab L et al. | β | 2019 | β |
| Induction via Functional Protein Stabilization of Hepatic Cytochromes P450 upon gp78/Autocrine Motility Factor Receptor (AMFR) Ubiquitin E3-Ligase Genetic Ablation in Mice: Therapeutic and Toxicological Relevance. | Kwon D et al. | β | 2019 | β |
| Mode-of-action analysis of the effects induced by nicotine in the in vitro micronucleus assay. | Smart DJ et al. | β | 2019 | β |
| Molecular mechanisms for nicotine intoxication. | Alkam T et al. | β | 2019 | β |
| Strain-specific altered nicotine metabolism in 3,3'-diindolylmethane (DIM) exposed mice. | Bloom AJ et al. | β | 2019 | β |
| Suppressed hepatocyte proliferation via a ROS-HNE-P21 pathway is associated with nicotine- and cotinine-enhanced alcoholic fatty liver in mice. | Chen X et al. | β | 2019 | β |
| The neurobiology of addiction. | Uhl GR et al. | β | 2019 | β |
| Association of genetic polymorphisms CYP2A6*2 rs1801272 and CYP2A6*9 rs28399433 with tobacco-induced lung Cancer: case-control study in an Egyptian population. | Ezzeldin N et al. | β | 2018 | β |
| Current knowledge of microRNA-mediated regulation of drug metabolism in humans. | Nakano M et al. | β | 2018 | β |
| Cytochrome P450s and Alcoholic Liver Disease. | Lu Y et al. | β | 2018 | β |
| Genetic Polymorphism of <i>CYP2A6</i> and Its Relationship with Nicotine Metabolism in Male Bataknese Smokers Suffered from Lung Cancer in Indonesia. | Soeroso NN et al. | β | 2018 | β |
| Genetic polymorphisms of the drug-metabolizing enzyme cytochrome P450 2A6 in a Tibetan Chinese population. | Xia R et al. | β | 2018 | β |
| Genome-wide association study of a nicotine metabolism biomarker in African American smokers: impact of chromosome 19 genetic influences. | Chenoweth MJ et al. | β | 2018 | β |
| In silico prediction of potential chemical reactions mediated by human enzymes. | Yu MS et al. | β | 2018 | β |
| Longitudinal Influence of Pregnancy on Nicotine Metabolic Pathways. | Taghavi T et al. | β | 2018 | β |
| Molecular Insights Into Memory-Enhancing Metabolites of Nicotine in Brain: A Systematic Review. | Majdi A et al. | β | 2018 | β |
| Nicotine enhances alcoholic fatty liver in mice: Role of CYP2A5. | Chen X et al. | β | 2018 | β |
| Preparing the Way: Exploiting Genomic Medicine to Stop Smoking. | Bierut LJ et al. | β | 2018 | β |
| Relationships Between Smoking Behaviors and Cotinine Levels Among Two American Indian Populations With Distinct Smoking Patterns. | Tanner JA et al. | β | 2018 | β |
| The Value of Biosamples in Smoking Cessation Trials: A Review of Genetic, Metabolomic, and Epigenetic Findings. | Saccone NL et al. | β | 2018 | β |
| Characterising the nicotine metabolite ratio and its association with treatment choice: A cross sectional analysis of Stop Smoking Services in England. | Shahab L et al. | β | 2017 | β |
| Disruption of retinal pigment epithelial cell properties under the exposure of cotinine. | Zhang XY et al. | β | 2017 | β |
| Distribution of polymorphic variants of CYP2A6 and their involvement in nicotine addiction. | LΓ³pez-Flores LA et al. | β | 2017 | β |
| Drug metabolism by flavin-containing monooxygenases of human and mouse. | Phillips IR et al. | β | 2017 | β |
| Functional Characterization of 34 CYP2A6 Allelic Variants by Assessment of Nicotine C-Oxidation and Coumarin 7-Hydroxylation Activities. | Hosono H et al. | β | 2017 | β |
| Ortho-Methylarylamines as Time-Dependent Inhibitors of Cytochrome P450 1A1 Enzyme. | Sridhar J et al. | β | 2017 | β |
| Pharmacogenetic Optimization of Smoking Cessation Treatment. | Chenoweth MJ et al. | β | 2017 | β |
| Protective Effect of White-fleshed Peach (<i>Prunus persica</i> (L.) Batsch) on Chronic Nicotine-induced Toxicity. | Kim HJ et al. | β | 2017 | β |
| Antimicrobial photodynamic therapy minimizes the deleterious effect of nicotine in female rats with induced periodontitis. | Gualberto EC et al. | β | 2016 | β |
| Contribution of Monoamine Oxidase Inhibition to Tobacco Dependence: A Review of the Evidence. | Hogg RC | β | 2016 | β |
| Genome-Wide Association of the Laboratory-Based Nicotine Metabolite Ratio in Three Ancestries. | Baurley JW et al. | β | 2016 | β |
| Genomic Landscape of Experimental Bladder Cancer in Rodents and Its Application to Human Bladder Cancer: Gene Amplification and Potential Overexpression of Cyp2a5/CYP2A6 Are Associated with the Invasive Phenotype. | Kanemoto K et al. | β | 2016 | β |
| Inactivation of CYP2A6 by the Dietary Phenylpropanoid trans-Cinnamic Aldehyde (Cinnamaldehyde) and Estimation of Interactions with Nicotine and Letrozole. | Chan J et al. | β | 2016 | β |
| Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling. | Upreti VV et al. | β | 2016 | β |
| Smokescreen: a targeted genotyping array for addiction research. | Baurley JW et al. | β | 2016 | β |
| The Nicotine Metabolite Ratio is Associated With Early Smoking Abstinence Even After Controlling for Factors That Influence the Nicotine Metabolite Ratio. | Chenoweth MJ et al. | β | 2016 | β |
| Variation in CYP2A6 and tobacco dependence throughout adolescence and in young adult smokers. | Chenoweth MJ et al. | β | 2016 | β |
| Biotransformation of xenobiotics in the human colon and rectum and its association with colorectal cancer. | Beyerle J et al. | β | 2015 | β |
| Computational predictions of the site of metabolism of cytochrome P450 2D6 substrates: comparative analysis, molecular docking, bioactivation and toxicological implications. | Ford KA et al. | β | 2015 | β |
| CYP2A6 genetic polymorphism is associated with decreased susceptibility toΒ squamous cell lung cancer in Japanese smokers. | Hosono H et al. | β | 2015 | β |
| CYP2A7 pseudogene transcript affects CYP2A6 expression in human liver by acting as a decoy for miR-126. | Nakano M et al. | β | 2015 | β |
| Drug Metabolizing Enzyme and Transporter Gene Variation, Nicotine Metabolism, Prospective Abstinence, and Cigarette Consumption. | Bergen AW et al. | β | 2015 | β |
| EFFECT OF CYP2A6*4 GENETIC POLYMORPHISMS ON SMOKING BEHAVIORS AND NICOTINE DEPENDENCE IN A GENERAL POPULATION OF JAPANESE MEN. | Ito T et al. | β | 2015 | β |
| Electronic cigarettes: The nicotyrine hypothesis. | Abramovitz A et al. | β | 2015 | β |
| Gene-smoking interactions identify several novel blood pressure loci in the Framingham Heart Study. | Sung YJ et al. | β | 2015 | β |
| Haemodynamic responses to tobacco smoke inhalation in male adolescents in Lusaka, Zambia. | Chikopela T et al. | β | 2015 | β |
| Regioselective Versatility of Monooxygenase Reactions Catalyzed by CYP2B6 and CYP3A4: Examples with Single Substrates. | Erratico CA et al. | β | 2015 | β |
| Effect of CYP2A6 genetic polymorphism on the metabolic conversion of tegafur to 5-fluorouracil and its enantioselectivity. | Yamamiya I et al. | β | 2014 | β |
| Finding genomic function for genetic associations in nicotine addiction research: the ENCODE project's role in future pharmacogenomic analysis. | Vandenbergh DJ et al. | β | 2014 | β |
| Known and novel sources of variability in the nicotine metabolite ratio in a large sample of treatment-seeking smokers. | Chenoweth MJ et al. | β | 2014 | β |
| Novel CYP2A6 variants identified in African Americans are associated with slow nicotine metabolism in vitro and in vivo. | Piliguian M et al. | β | 2014 | β |
| The relationship between the nicotine metabolite ratio and three self-report measures of nicotine dependence across sex and race. | Schnoll RA et al. | β | 2014 | β |
| Advances in genetic studies of substance abuse in China. | Sun Y et al. | β | 2013 | β |
| Alaska Native smokers and smokeless tobacco users with slower CYP2A6 activity have lower tobacco consumption, lower tobacco-specific nitrosamine exposure and lower tobacco-specific nitrosamine bioactivation. | Zhu AZ et al. | β | 2013 | β |
| Association of CYP2A6*4 with susceptibility of lung cancer: a meta-analysis. | Wang L | β | 2013 | β |
| Catalytic mechanism of cytochrome P450 for N-methylhydroxylation of nicotine: reaction pathways and regioselectivity of the enzymatic nicotine oxidation. | Li D et al. | β | 2013 | β |
| CYP2A6 deletion polymorphism is associated with decreased susceptibility of lung cancer in Asian smokers: a meta-analysis. | Liu YL et al. | β | 2013 | β |
| Hormonal regulation of hepatic drug biotransformation and transport systems. | Ruiz ML et al. | β | 2013 | β |
| Nicotine metabolism and addiction among adolescent smokers. | Rubinstein ML et al. | β | 2013 | β |
| Predictors of cessation in African American light smokers enrolled in a bupropion clinical trial. | Faseru B et al. | β | 2013 | β |
| Serum androgen level is determined by autosomal dominant inheritance and regulates sex-related CYP genes in pigs. | Kojima M et al. | β | 2013 | β |
| The ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: the influence of genetics, race, and sex. | Zhu AZ et al. | β | 2013 | β |
| An LC-MS/MS method for concurrent determination of nicotine metabolites and the role of CYP2A6 in nicotine metabolite-mediated oxidative stress in SVGA astrocytes. | Ande A et al. | β | 2012 | β |
| Application of the buccal micronucleus cytome assay and analysis of PON1Gln192Arg and CYP2A6*9(-48T>G) polymorphisms in tobacco farmers. | Da Silva FR et al. | β | 2012 | β |
| Cytochrome P4501A2 phenotype and bladder cancer risk: The Shanghai bladder cancer study. | Tao L et al. | β | 2012 | β |
| Gene-centric analysis of serum cotinine levels in African and European American populations. | Hamidovic A et al. | β | 2012 | β |
| General mechanisms of nicotine-induced fibrogenesis. | Jensen K et al. | β | 2012 | β |
| Genetic polymorphisms of drug-metabolizing phase I enzymes CYP2E1, CYP2A6 and CYP3A5 in South Indian population. | Krishnakumar D et al. | β | 2012 | β |
| Interplay between smoking-induced genotoxicity and altered signaling in pancreatic carcinogenesis. | Momi N et al. | β | 2012 | β |
| Nicotinic acetylcholine receptor variants are related to smoking habits, but not directly to COPD. | Budulac SE et al. | β | 2012 | β |
| PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6. | McDonagh EM et al. | β | 2012 | β |
| Positive and negative effects of alcohol and nicotine and their interactions: a mechanistic review. | Hurley LL et al. | β | 2012 | β |
| The genetics of substance dependence. | Wang JC et al. | β | 2012 | β |
| Toxicity of nicotine by repeated intratracheal instillation to f344 rats. | Yokohira M et al. | β | 2012 | β |
| Catalytic mechanism of cytochrome P450 for 5'-hydroxylation of nicotine: fundamental reaction pathways and stereoselectivity. | Li D et al. | β | 2011 | β |
| Differences between Spaniards and Ecuadorians in CYP2A6 allele frequencies: comparison with other populations. | Soriano A et al. | β | 2011 | β |
| Effect of alcohol on drug efflux protein and drug metabolic enzymes in U937 macrophages. | Jin M et al. | β | 2011 | β |
| Human CYP2A6 is regulated by nuclear factor-erythroid 2 related factor 2. | Yokota S et al. | β | 2011 | β |
| Identification of novel CYP2A6 inhibitors by virtual screening. | Rahnasto MK et al. | β | 2011 | β |
| Orally formulated artemisinin in healthy fasting Vietnamese male subjects: a randomized, four-sequence, open-label, pharmacokinetic crossover study. | Hien TT et al. | β | 2011 | β |
| Pharmacogenetics of alcohol, nicotine and drug addiction treatments. | Sturgess JE et al. | β | 2011 | β |
| Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes. | Lee IS et al. | β | 2011 | β |
| Association between nicotine metabolism and CYP2A6*1 and CYP2A6*4 genotypes in an Iranian population. | Heravi RE et al. | β | 2010 | β |
| Effects of nicotine on cytochrome P450 2A6 and 2E1 activities. | Hukkanen J et al. | β | 2010 | β |
| Fundamental reaction pathways for cytochrome P450-catalyzed 5'-hydroxylation and N-demethylation of nicotine. | Li D et al. | β | 2010 | β |
| Genome-wide meta-analyses identify multiple loci associated with smoking behavior. | Tobacco and Genetics Consortium | β | 2010 | β |
| Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors. | Al Koudsi N et al. | β | 2010 | β |
| Hepatic CYP2B6 is altered by genetic, physiologic, and environmental factors but plays little role in nicotine metabolism. | Al Koudsi N et al. | β | 2010 | β |
| Internet suicide guidelines: report of a life-threatening poisoning using tobacco extract. | Schneider S et al. | β | 2010 | β |
| Pharmacogenetics of drug dependence: role of gene variations in susceptibility and treatment. | Khokhar JY et al. | β | 2010 | β |
| Pharmacogenetics of smoking cessation therapy. | Kortmann GL et al. | β | 2010 | β |
| Role of CYP2A5 in the clearance of nicotine and cotinine: insights from studies on a Cyp2a5-null mouse model. | Zhou X et al. | β | 2010 | β |
| A novel CYP2A6 allele (CYP2A6*35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo. | Al Koudsi N et al. | β | 2009 | β |
| Conceptual DFT properties-based 3D QSAR: analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme. | Van Damme S et al. | β | 2009 | β |
| Genetic variation as a predictor of smoking cessation success. A promising preventive and intervention tool for chronic respiratory diseases? | Quaak M et al. | β | 2009 | β |
| Genome-wide linkage of cotinine pharmacokinetics suggests candidate regions on chromosomes 9 and 11. | He Y et al. | β | 2009 | β |
| Implications of gene-drug interactions in smoking cessation for improving the prevention of chronic degenerative diseases. | Quaak M et al. | β | 2009 | β |
| Nicotine chemistry, metabolism, kinetics and biomarkers. | Benowitz NL et al. | β | 2009 | β |
| Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes. | Ray R et al. | β | 2009 | β |
| Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. | Schnoll RA et al. | β | 2009 | β |
| Polymorphism of human cytochrome P450 enzymes and its clinical impact. | Zhou SF et al. | β | 2009 | β |
| Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. | Tarning J et al. | β | 2009 | β |
| Simultaneous and sensitive measurement of nicotine, cotinine, trans-3'-hydroxycotinine and norcotinine in human plasma by liquid chromatography-tandem mass spectrometry. | Shakleya DM et al. | β | 2009 | β |
| A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent. | Ho MK et al. | β | 2008 | β |
| CYP2A6 activity in a healthy Spanish population: effect of age, sex, smoking, and oral contraceptives. | Sinues B et al. | β | 2008 | β |
| CYP2A6 polymorphisms and risk for tobacco-related cancers. | Rossini A et al. | β | 2008 | β |
| Identification of inhibitors of the nicotine metabolising CYP2A6 enzyme--an in silico approach. | Rahnasto M et al. | β | 2008 | β |
| Identification of novel CYP2A6*1B variants: the CYP2A6*1B allele is associated with faster in vivo nicotine metabolism. | Mwenifumbo JC et al. | β | 2008 | β |
| Inhibition and induction of human cytochrome P450 enzymes: current status. | Pelkonen O et al. | β | 2008 | β |
| Nicotinic receptors containing the alpha7 subunit: a model for rational drug design. | Sharma G et al. | β | 2008 | β |
| Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent. | Mwenifumbo JC et al. | β | 2008 | β |
| Rate of nicotine metabolism and withdrawal symptoms in adolescent light smokers. | Rubinstein ML et al. | β | 2008 | β |
| A novel duplication type of CYP2A6 gene in African-American population. | Fukami T et al. | β | 2007 | β |
| Application of nicotine enantiomers, derivatives and analogues in therapy of neurodegenerative disorders. | Pogocki D et al. | β | 2007 | β |
| Aryl hydrocarbon receptor nuclear translocator and upstream stimulatory factor regulate Cytochrome P450 2a5 transcription through a common E-box site. | Arpiainen S et al. | β | 2007 | β |
| CYP2A13 metabolizes the substrates of human CYP1A2, phenacetin, and theophylline. | Fukami T et al. | β | 2007 | β |
| Gene-gene interactions between CYP2B6 and CYP2A6 in nicotine metabolism. | Ring HZ et al. | β | 2007 | β |
| Genetic variability in CYP2A6 and the pharmacokinetics of nicotine. | Mwenifumbo JC et al. | β | 2007 | β |
| Human CYP2A6 is induced by estrogen via estrogen receptor. | Higashi E et al. | β | 2007 | β |
| Nicotine metabolism and CYP2A6 activity in a population of black African descent: impact of gender and light smoking. | Mwenifumbo JC et al. | β | 2007 | β |
| Non-nicotinic therapies for smoking cessation. | Siu EC et al. | β | 2007 | β |
| Overview of the pharmacogenomics of cigarette smoking. | Ho MK et al. | β | 2007 | β |
| A validated method for the determination of nicotine, cotinine, trans-3'-hydroxycotinine, and norcotinine in human plasma using solid-phase extraction and liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry. | Kim I et al. | β | 2006 | β |
| Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics. | Al Koudsi N et al. | β | 2006 | β |
| CYP2A7 polymorphic alleles confound the genotyping of CYP2A6*4A allele. | Fukami T et al. | β | 2006 | β |
| Efficient activation of aflatoxin B1 by cytochrome P450 2A13, an enzyme predominantly expressed in human respiratory tract. | He XY et al. | β | 2006 | β |
| Ethnic differences in arterial stiffness and wave reflections after cigarette smoking. | Lemogoum D et al. | β | 2006 | β |
| Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. | Malaiyandi V et al. | β | 2006 | β |
| Inactivation of CYP2A6 and CYP2A13 during nicotine metabolism. | von Weymarn LB et al. | β | 2006 | β |
| Isoflavones inhibit nicotine C-oxidation catalyzed by human CYP2A6. | Nakajima M et al. | β | 2006 | β |
| Risk factors for tobacco dependence in adolescent smokers. | Karp I et al. | β | 2006 | β |
| Tailoring nicotine replacement therapy: rationale and potential approaches. | McClure JB et al. | β | 2006 | β |
| The genetics of nicotine dependence: relationship to pancreatic cancer. | MacLeod SL et al. | β | 2006 | β |
| Analysis of coumarin 7-hydroxylation activity of cytochrome P450 2A6 using random mutagenesis. | Kim D et al. | β | 2005 | β |
| A novel CYP2A6*20 allele found in African-American population produces a truncated protein lacking enzymatic activity. | Fukami T et al. | β | 2005 | β |
| Association of CYP2A6*1B genetic variant with the amount of smoking in French adults from the Stanislas cohort. | Gambier N et al. | β | 2005 | β |
| Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity. | Fukami T et al. | β | 2005 | β |
| CYP2A6 AND CYP2B6 are involved in nornicotine formation from nicotine in humans: interindividual differences in these contributions. | Yamanaka H et al. | β | 2005 | β |
| CYP2A6 genetic polymorphisms and correlation with smoking status in Brazilians. | Vasconcelos GM et al. | β | 2005 | β |
| Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method. | Mwenifumbo JC et al. | β | 2005 | β |
| [Genetic basis of tobacco dependence]. | Barrueco M et al. | β | 2005 | β |
| Genetic influences on smoking: a brief review. | Al Koudsi N et al. | β | 2005 | β |
| Genetic polymorphism of CYP2A6 as one of the potential determinants of tobacco-related cancer risk. | Kamataki T et al. | β | 2005 | β |
| Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. | Malaiyandi V et al. | β | 2005 | β |
| Influence of menstrual cycle on cytochrome P450 2A6 activity and cardiovascular effects of nicotine. | Hukkanen J et al. | β | 2005 | β |
| Inter-gene correlation on oligonucleotide arrays: how much does normalization matter? | Gold DL et al. | β | 2005 | β |
| Interindividual variability in nicotine metabolism: C-oxidation and glucuronidation. | Nakajima M et al. | β | 2005 | β |
| Metabolism and disposition kinetics of nicotine. | Hukkanen J et al. | β | 2005 | β |
| Metabolism of nicotine and cotinine by human cytochrome P450 2A13. | Bao Z et al. | β | 2005 | β |
| Nicotine 5'-oxidation and methyl oxidation by P450 2A enzymes. | Murphy SE et al. | β | 2005 | β |
| Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence. | Swan GE et al. | β | 2005 | β |
| Regulation of the Cyp2a5 gene involves an aryl hydrocarbon receptor-dependent pathway. | Arpiainen S et al. | β | 2005 | β |
| Three haplotypes associated with CYP2A6 phenotypes in Caucasians. | Haberl M et al. | β | 2005 | β |
| Trans-3'-hydroxycotinine O- and N-glucuronidations in human liver microsomes. | Yamanaka H et al. | β | 2005 | β |
| A nicotine C-oxidase gene (CYP2A6) polymorphism important for promoter activity. | Pitarque M et al. | β | 2004 | β |
| Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. | Kim K et al. | β | 2004 | β |
| Effects of cigarette smoking and exposure to cadmium and lead on phenotypic variability of hepatic CYP2A6 and renal function biomarkers in men. | Satarug S et al. | β | 2004 | β |
| Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. | Schoedel KA et al. | β | 2004 | β |
| Evidence for concurrent effects of exposure to environmental cadmium and lead on hepatic CYP2A6 phenotype and renal function biomarkers in nonsmokers. | Satarug S et al. | β | 2004 | β |
| Human variability for metabolic pathways with limited data (CYP2A6, CYP2C9, CYP2E1, ADH, esterases, glycine and sulphate conjugation). | Dorne JL et al. | β | 2004 | β |
| Identification of Val117 and Arg372 as critical amino acid residues for the activity difference between human CYP2A6 and CYP2A13 in coumarin 7-hydroxylation. | He XY et al. | β | 2004 | β |
| Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted. | Yamanaka H et al. | β | 2004 | β |
| Nicotine, its metabolism and an overview of its biological effects. | Yildiz D | β | 2004 | β |
| Novel human CYP2A6 alleles confound gene deletion analysis. | Nakajima M et al. | β | 2004 | β |
| Polymorphic NF-Y dependent regulation of human nicotine C-oxidase (CYP2A6). | von Richter O et al. | β | 2004 | β |
| Substrates of human cytochromes P450 from families CYP1 and CYP2: analysis of enzyme selectivity and metabolism. | Lewis DF et al. | β | 2004 | β |
| Alcohol, nicotine, caffeine, and mental disorders. | Crocq MA | β | 2003 | β |
| Association of CYP2A6 gene deletion with cigarette smoking status in Japanese adults. | Ando M et al. | β | 2003 | β |
| Catalog of 680 variations among eight cytochrome p450 ( CYP) genes, nine esterase genes, and two other genes in the Japanese population. | Saito S et al. | β | 2003 | β |
| Clinical considerations in study designs that use cotinine as a biomarker. | Bramer SL et al. | β | 2003 | β |
| Comparative American and Japanese tobacco smoke uptake parameters after overnight tobacco deprivation. | Domino EF et al. | β | 2003 | β |
| Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9). | Kiyotani K et al. | β | 2003 | β |
| Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration. | Schoedel KA et al. | β | 2003 | β |
| Effects of nicotine infusion on the metabolism of the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in rats. | Keyler D et al. | β | 2003 | β |
| Environmental and genetic determinants of tobacco use: methodology for a multidisciplinary, longitudinal family-based investigation. | Swan GE et al. | β | 2003 | β |
| Genetic influences on smoking behavior and nicotine dependence: a review. | Yoshimasu K et al. | β | 2003 | β |
| Nicotine metabolism, human drug metabolism polymorphisms, and smoking behaviour. | Tricker AR | β | 2003 | β |
| A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur. | Daigo S et al. | β | 2002 | β |
| Characterization of nicotine and cotinine N-glucuronidations in human liver microsomes. | Nakajima M et al. | β | 2002 | β |
| Clinical phenotyping strategies in selection of tobacco smokers for future genotyping studies. | Domino EF et al. | β | 2002 | β |
| Effect of nicotine, cotinine and phenethyl isothiocyanate on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism in the Syrian golden hamster. | Richter E et al. | β | 2002 | β |
| Effects of (-)-nicotine and (-)-cotinine on 6-hydroxydopamine-induced oxidative stress and neurotoxicity: relevance for Parkinson's disease. | Soto-Otero R et al. | β | 2002 | β |
| Effects of whole deletion of CYP2A6 on nicotine metabolism in humans. | Zhang X et al. | β | 2002 | β |
| Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism. | Yoshida R et al. | β | 2002 | β |
| Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior. | Tyndale RF et al. | β | 2002 | β |
| Genotyping human CYP2A6 variants. | Goodz SD et al. | β | 2002 | β |
| High-performance liquid chromatographic assay for N-glucuronidation of nicotine and cotinine in human liver microsomes. | Nakajima M et al. | β | 2002 | β |
| Interindividual differences in nicotine metabolism and genetic polymorphisms of human CYP2A6. | Nakajima M et al. | β | 2002 | β |
| Molecular orbital calculations and nicotine metabolism: a rationale for experimentally observed metabolite ratios. | Lewis DF et al. | β | 2002 | β |
| Novel mutations of the CYP2A6 gene in a Thai population with lowered capacity of coumarin 7-hydroxylation. | Kiyotani K et al. | β | 2002 | β |
| Summary of information on human CYP enzymes: human P450 metabolism data. | Rendic S | β | 2002 | β |
| A novel single nucleotide polymorphism altering stability and activity of CYP2a6. | Ariyoshi N et al. | β | 2001 | β |
| Comparison of cytochrome P450 2A6 polymorphism frequencies in Caucasians and African-Americans using a new one-step PCR-RFLP genotyping method. | Paschke T et al. | β | 2001 | β |
| CYP2A6*6, a novel polymorphism in cytochrome p450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity. | Kitagawa K et al. | β | 2001 | β |
| Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population. | Tan W et al. | β | 2001 | β |
| Genetic clues to the molecular basis of tobacco addiction and progress towards personalized therapy. | Walton R et al. | β | 2001 | β |
| Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. | Pitarque M et al. | β | 2001 | β |
| Nicotine metabolism and CYP2A6 allele frequencies in Koreans. | Kwon JT et al. | β | 2001 | β |
| Polymorphisms of CYP2A6 and its practical consequences. | Raunio H et al. | β | 2001 | β |
| The use of gene knockout mice to unravel the mechanisms of toxicity and chemical carcinogenesis. | Gonzalez FJ | β | 2001 | β |
| Trans-3'-hydroxycotinine: disposition kinetics, effects and plasma levels during cigarette smoking. | Benowitz NL et al. | β | 2001 | β |
| 2'-Hydroxylation of nicotine by cytochrome P450 2A6 and human liver microsomes: formation of a lung carcinogen precursor. | Hecht SS et al. | β | 2000 | β |
| CYP2A6: a human coumarin 7-hydroxylase. | Pelkonen O et al. | β | 2000 | β |
| Development of a Salmonella tester strain sensitive to promutagenic N-nitrosamines: expression of recombinant CYP2A6 and human NADPH-cytochrome P450 reductase in S. typhimurium YG7108. | Kushida H et al. | β | 2000 | β |
| Functional variants at CYP2A6: new genotyping methods, population genetics, and relevance to studies of tobacco dependence. | Zabetian CP et al. | β | 2000 | β |
| Improved highly sensitive method for determination of nicotine and cotinine in human plasma by high-performance liquid chromatography. | Nakajima M et al. | β | 2000 | β |
| Mimicking gene defects to treat drug dependence. | Sellers EM et al. | β | 2000 | β |
| Polymorphisms in genes involved in neurotransmission in relation to smoking. | Arinami T et al. | β | 2000 | β |
| Regional and cellular induction of nicotine-metabolizing CYP2B1 in rat brain by chronic nicotine treatment. | Miksys S et al. | β | 2000 | β |
| Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C. | Ariyoshi N et al. | β | 2000 | β |
| Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. | Oscarson M et al. | β | 1999 | β |
| Expression of CYP2A genes in human liver and extrahepatic tissues. | Koskela S et al. | β | 1999 | β |
| Expression of cytochrome P450 2A6 in Escherichia coli: purification, spectral and catalytic characterization, and preparation of polyclonal antibodies. | Soucek P | β | 1999 | β |
| Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity. | Wormhoudt LW et al. | β | 1999 | β |
| Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. | Oscarson M et al. | β | 1999 | β |
| The significance of the homozygous CYP2A6 deletion on nicotine metabolism: a new genotyping method of CYP2A6 using a single PCR-RFLP. | Kitagawa K et al. | β | 1999 | β |
| Cytochrome P4502A6 (CYP2A6) expression in human hepatocellular carcinoma. | Raunio H et al. | β | 1998 | β |
| Genetic influences on smoking: candidate genes. | Rossing MA | β | 1998 | β |
| Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese. | Yokoi T et al. | β | 1998 | β |
| Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase. | Oscarson M et al. | β | 1998 | β |
| Comparison of CYP2A6 catalytic activity on coumarin 7-hydroxylation in human and monkey liver microsomes. | Li Y et al. | β | 1997 | β |